Publications by authors named "Tara M Rogers"
Objectives: Ceftazidime/avibactam and meropenem/vaborbactam are preferred agents for carbapenemase (KPC)-producing (KPC-) infections and are often used in combination with other agents. We aimed to characterize the synergy of combinations against KPC- with varying genotypes.
Methods: KPC- that harboured WT, IS or glycine-aspartic acid duplication (GD) genotypes were selected.
Article Synopsis
- New β-lactam/β-lactamase inhibitors, such as ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/relebactam, are showing promise in treating KPC-producing infections, but their effectiveness varies based on the specific genetic make-up of the bacteria.
- The study analyzed 104 KPC- isolates to understand how differences in their genetic profiles affected antibiotic efficacy, and found that mutations significantly influenced resistance levels.
- Time-kill tests revealed that ceftazidime/avibactam was effective across different isolates, while imipenem/relebactam struggled with certain mutations, indicating the need for targeted treatment strategies based on genetic
Objectives: We evaluated the clinical characteristics and outcomes of patients with COVID-19 who received three-drug combination regimens for treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections during a single-centre outbreak. Our objective was to describe the clinical outcomes and molecular characteristics and in vitro synergy of antibiotics against CRAB isolates.
Materials And Methods: Patients with severe COVID-19 admitted between April and July 2020 with CRAB infections were retrospectively evaluated.